Close Menu

NEW YORK (GenomeWeb) – Aiming to drive greater adoption of tests for sexually transmitted diseases, Binx Health believes it is well placed to benefit from an expansion of services at US health clinics with the development of its rapid point-of-care testing platform, according to CEO Jeffrey Luber.

The Boston-based firm — formerly called Atlas Genetics — recently received a CE IVD mark for its chlamydia and gonorrhea (CT/NG) test running on its Binx io point-of-care platform.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Jul
25

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.

Jul
31
Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.